Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Practice Guidelines for Diseases Caused by Aspergillus

Practice Guidelines for Diseases Caused by Aspergillus 1,2,9,a 3,9 David A. Stevens, Virginia L. Kan, From the Santa Clara Valley Medical Center, San Jose, 4,9 5,12 and Stanford University Medical School, Stanford, California; Marc A. Judson, Vicki A. Morrison, 6,9 13 Department of Veterans Affairs Medical Center and Georgetown Stephen Dummer, David W. Denning, University Medical School, Washington, DC; Medical University 7,9 8,9 John E. Bennett, Thomas J. Walsh, of South Carolina, Charleston, South Carolina; Department 9,10 9,11 Thomas F. Patterson, and George A. Pankey of Veterans Affairs Medical Center and University of Minnesota, Minneapolis, Minnesota; Vanderbilt University Medical School, Nashville, Tennessee; National Institute of Allergy and Infectious 8 9 Diseases and National Cancer Institute, National Institute of Allergy and Infectious Diseases Mycoses Study Group, National Institutes of Health, Bethesda, Maryland; University of Texas Health Science Center, San Antonio, Texas; Ochsner Clinic, New Orleans, Louisiana; Cancer and Leukemia Group B, Chicago, Illinois, USA; and North Manchester General Hospital and University of Manchester Medical School, Manchester, England, UK Executive Summary (BII). Oral itraconazole is attractive for continuing therapy in the patient who responds to initial iv therapy (CIII). Therapy Aspergillosis comprises a variety of manifestations of infec- should be prolonged beyond resolution of disease and reversible tion. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Infectious Diseases Oxford University Press

Practice Guidelines for Diseases Caused by Aspergillus

Download PDF
14 pages

Loading next page...
 
/lp/oxford-university-press/practice-guidelines-for-diseases-caused-by-aspergillus-cJF0EAt90h

References (212)

Publisher
Oxford University Press
Copyright
© Published by Oxford University Press.
ISSN
1058-4838
eISSN
1537-6591
DOI
10.1086/313756
pmid
10770732
Publisher site
See Article on Publisher Site

Abstract

1,2,9,a 3,9 David A. Stevens, Virginia L. Kan, From the Santa Clara Valley Medical Center, San Jose, 4,9 5,12 and Stanford University Medical School, Stanford, California; Marc A. Judson, Vicki A. Morrison, 6,9 13 Department of Veterans Affairs Medical Center and Georgetown Stephen Dummer, David W. Denning, University Medical School, Washington, DC; Medical University 7,9 8,9 John E. Bennett, Thomas J. Walsh, of South Carolina, Charleston, South Carolina; Department 9,10 9,11 Thomas F. Patterson, and George A. Pankey of Veterans Affairs Medical Center and University of Minnesota, Minneapolis, Minnesota; Vanderbilt University Medical School, Nashville, Tennessee; National Institute of Allergy and Infectious 8 9 Diseases and National Cancer Institute, National Institute of Allergy and Infectious Diseases Mycoses Study Group, National Institutes of Health, Bethesda, Maryland; University of Texas Health Science Center, San Antonio, Texas; Ochsner Clinic, New Orleans, Louisiana; Cancer and Leukemia Group B, Chicago, Illinois, USA; and North Manchester General Hospital and University of Manchester Medical School, Manchester, England, UK Executive Summary (BII). Oral itraconazole is attractive for continuing therapy in the patient who responds to initial iv therapy (CIII). Therapy Aspergillosis comprises a variety of manifestations of infec- should be prolonged beyond resolution of disease and reversible tion.

Journal

Clinical Infectious Diseases – Oxford University Press

Published: Apr 1, 2000

There are no references for this article.